INTCO MEDICAL(SZ:300677) Orient Securities·2026-03-07 08:50Investment Rating - The report gives a "Buy" rating for the company for the first time, with a target price of 53.46 CNY based on an 18x P/E ratio for 2026 [4][7]. Core Insights - The company is positioned as a leader in the disposable glove market, benefiting from a significant increase in production capacity during the pandemic and a subsequent recovery in demand [10][14]. - The company has advanced production lines that provide a cost advantage, which is expected to strengthen its market position further [10][48]. - The company is expected to see gradual improvements in both sales volume and pricing, indicating strong earnings elasticity [10][66]. Financial Forecast and Investment Recommendations - The company is projected to achieve earnings per share of 1.98 CNY, 2.97 CNY, and 3.37 CNY for the years 2025, 2026, and 2027 respectively [4]. - Revenue is expected to grow from 6,919 million CNY in 2023 to 13,563 million CNY in 2027, with a compound annual growth rate (CAGR) of 36% from 2019 to 2024 [6][28]. - The net profit attributable to the parent company is forecasted to increase from 383 million CNY in 2023 to 2,209 million CNY in 2027, reflecting a strong recovery trajectory [6][28]. Company Overview - The company primarily focuses on personal protective products, with disposable gloves accounting for approximately 90% of its revenue [14][21]. - The company operates six major production bases and exports to over 120 countries, with a significant portion of its revenue coming from international markets [10][14]. - The company has a strong financial position, with a market capitalization of 30,328 million CNY and a total share capital of 65,516 million shares [7]. Market Dynamics - The global disposable glove market is expected to recover, with sales volume projected to return to pre-pandemic levels by 2025, indicating a stabilization in pricing [39][40]. - The company has a competitive edge due to its advanced production technology and cost management strategies, which are expected to enhance profitability as the market stabilizes [10][65]. Production and Cost Advantages - The company utilizes third-generation production lines that are energy-efficient and have a high yield rate of over 99% [48][52]. - Cost management initiatives, including energy-saving upgrades and self-supply of key raw materials, further enhance the company's competitive position [60][61]. Sales and Market Share - The company is expected to capture a larger market share as it continues to expand its production capacity and diversify its market presence [10][66]. - The domestic market shows potential for steady growth, supported by an increasing number of healthcare professionals and low per capita glove usage compared to global averages [67][70]. Conclusion - The report indicates a positive outlook for the company, driven by its strong market position, advanced production capabilities, and favorable financial projections, making it an attractive investment opportunity [4][10][66].